Quantum Genesis AI Corp. (OTC: QGAI) announced today that it is taking steps to address the Caveat Emptor designation placed on its securities by OTC Markets Group on February 12, 2026. The company, which focuses on artificial intelligence, computational modeling, and scientific innovation, stated that it has made several attempts to communicate with OTC Markets to understand the basis for the designation, which OTC Markets has indicated relates to a "public interest concern."
According to the press release, OTC Markets recently informed Quantum Genesis AI that it may formally request a review of the designation starting March 13, 2026. The company intends to engage with OTC Markets at the earliest opportunity to initiate the review process. "We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation," said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. "Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process."
The Caveat Emptor designation is applied by OTC Markets to alert investors that there may be a public interest concern associated with a company. For Quantum Genesis AI, this designation could impact investor confidence and the trading liquidity of its stock. The company's response underscores its commitment to transparency and cooperation with regulators. "We remain committed to maintaining transparency with our shareholders and the broader investment community," the company stated.
Quantum Genesis AI Corp. is based in San Diego, California, and its strategy includes leveraging advanced data-driven tools to support research and technology development. The company emphasized its dedication to responsible corporate governance. For more information, investors can visit the company's website at www.qgaicorp.com and its profile on OTC Markets at www.otcmarkets.com/stock/QGAI.
The company's statement comes as it works to resolve the regulatory concern and restore normal trading status. The outcome of the review process could have significant implications for the company's market perception and access to capital. Quantum Genesis AI intends to provide updates as additional information becomes available.
